Gaxos Labs Launches “Photoshoots,” Bringing Studio-Grade AI Photography to Art-Gen
Globenewswire· 2025-11-06 13:00
Core Insights - Gaxos.ai Inc. has launched a new feature called Photoshoots for its Art-Gen platform, enhancing its capabilities in the AI-driven creator economy, which is projected to exceed $480 billion by 2027 [2][3] Company Overview - Gaxos.ai Inc. is focused on developing artificial intelligence applications across various high-growth sectors, including health, wellness, and gaming [7] Product Features - The Photoshoots feature allows users to create studio-quality images and animations quickly, transforming Art-Gen into a comprehensive visual studio [3] - Key features include professional photoshoot transformation, subject likeness preservation, optional creative direction, continuous iteration, instant animation, smart image transformation, one-click upscaling, dynamic video creation, AI prompt writer, style presets, and a live creative gallery [5]
OptimumBank Holdings, Inc., to Announce Third Quarter 2025 Results and Host Earnings Webcast on November 13, 2025
Globenewswire· 2025-11-06 13:00
FT. LAUDERDALE, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- OptimumBank Holdings, Inc. (NYSE American: OPHC), announced today that it will release its financial results for the third quarter ended September 30, 2025, before the market opens on Thursday, November 13, 2025. The Company’s management team will host a conference call and live webcast that morning at 10:00 A.M. Eastern Time to review the quarterly results and provide a business update. Current and prospective investors are invited to attend the webca ...
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates
Globenewswire· 2025-11-06 13:00
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced financial results for the third quarter ended on September 30, 2025 and provided recent corporate updates. “Following our recent initial public offering, we are well-positioned to continue executing on our strategy to advance LB-102 into a Phase 3 trial in acute schizophrenia, as well as a Phase 2 trial in bipolar depression,” said Heather Turner, Chief Executive Officer ...
Ascent Solar Technologies and CisLunar Industries Enter Teaming Agreement to Bring Power Solutions that Lengthen Missions to U.S. Space Market
Globenewswire· 2025-11-06 13:00
THORNTON, Colo., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ascent Solar Technologies (“Ascent”), the leading U.S. innovator in the design and manufacturing of featherweight, flexible thin-film photovoltaic (PV) solutions, today announced the signing of a teaming agreement with CisLunar Industries (“CisLunar”), a leader in developing advanced hardware and embedded control software for power conversion and conditioning. The agreement aims to bring each of the Colorado-based companies’ technologies together to achieve ...
Zscaler to Host First Quarter Fiscal Year 2026 Earnings Conference Call
Globenewswire· 2025-11-06 13:00
Earnings Results to be Released on Tuesday, November 25, After the Close of the MarketSAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, will release first quarter fiscal year 2026 earnings after the market closes on Tuesday, November 25, 2025. The company will host an investor conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results. Date:Tuesday, November 25, 2025Time:1:30 p.m. PTWebcast:https://ir.zscal ...
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Globenewswire· 2025-11-06 13:00
TEL AVIV, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that it recently received a No-Objection Letter from Health Canada, the country’s primary regulatory authority for drugs and medical products, for the Company’s planned Phase 2 clinical study of NS002, its investigational intranasal epinephrine p ...
Rare Stock Picks In October 2025 - From 26 Discerning Analysts
Seeking Alpha· 2025-11-06 13:00
Healthcare - ImmunityBio (IBRX) is considered a speculative buy for aggressive investors, with significant upside potential driven by its lead therapy and promising early data from the t-haNK program [4] - UnitedHealth (UNH) is trading below its intrinsic value with a projected 20% upside, focusing on aggressive repricing of plans, expanding value-based care, and implementing AI to improve margins and operational efficiency [4] Financials - SLR Investment (SLRC) offers an attractive ~11% dividend yield, trades below book value, and is noted for its conservative leverage and above-average cash holdings among BDC peers [6] - Brighthouse Financial (BHF) is undervalued at 0.33x adjusted book value per share, with strong fundamentals highlighted by record annuity sales, robust capital ratios, and aggressive buybacks, indicating potential for 30-50%+ upside [6] - Upstart (UPST) is seen as having overly prudent guidance, with growth not fully priced in, supported by its AI-driven underwriting and rising conversion rates [7]
Greenridge Exploration Highlights Successful Results of Airborne Electromagnetic and Radiometric Survey for the Flying Vee Project
Globenewswire· 2025-11-06 13:00
VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | FRA: HW3 | OTCQB: GXPLF), is pleased to announce the results of a helicopter-borne time-domain electromagnetic and radiometric survey (collectively, the “Survey”) from the Flying Vee Project (“Flying Vee”, or the “Project”). Axiom Exploration Group Ltd. of Saskatoon, Saskatchewan, Canada (“Axiom”) performed a high-resolution Xcite™ survey at the Project in Q3 2025. The 2025 ...
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion
Globenewswire· 2025-11-06 13:00
Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansionHORSHAM, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in excimer laser therapy for inflammatory and autoimmune dermatologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its CY 2026 Medicare Physician Fee Schedule Final Rule confirming continued ...
American Airlines: Job Cuts Don't Change The Buy Case
Seeking Alpha· 2025-11-06 13:00
Core Insights - American Airlines is cutting hundreds of corporate jobs, which initially led to a 4% decline in stock price, attributed to broader market weakness rather than company-specific issues [1]. Company Summary - American Airlines (NYSE: AAL) is undergoing a significant workforce reduction, impacting corporate positions [1]. - The stock performance reflects market trends, indicating that the job cuts may not be the sole reason for the stock's decline [1]. Industry Context - The aerospace, defense, and airline sectors are characterized by significant growth prospects, and developments in these areas can influence investment strategies [1].